Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kirsten A. Weigel-Kelley"'
Autor:
Baozheng Li, Zongchao Han, Arun Srivastava, Li Zhong, Kenneth H. Warrington, Wenqin Ma, Kirsten A. Weigel-Kelley, Weihong Zhao, Jianqing Wu
Publikováno v:
Human Gene Therapy. 18:171-182
Self-complementary adeno-associated viral (scAAV) vectors bypass the requirement for viral second-strand DNA synthesis, but the packaging capacity of these vectors ( approximately 2.4 kb) is significantly smaller than that of conventional AAV vectors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c2f0df9cb8b586dfb2bd7369d67ab6
https://doi.org/10.1089/hum.2006.088
https://doi.org/10.1089/hum.2006.088
Autor:
Xiaomiao Li, Mervin C. Yoder, Baozheng Li, Arun Srivastava, Daniela Bischof, Li Zhong, Kenneth H. Warrington, Irene Zolotukhin, Keyun Qing, Njeri Maina, Weihong Zhao, Yanjun Li, Weiming Li, William B. Slayton, Jianqing Wu, Kirsten A. Weigel-Kelley
Publikováno v:
Human Gene Therapy. 17:321-333
Conflicting data exist on hematopoietic cell transduction by AAV serotype 2 (AAV2) vectors, and additional AAV serotype vectors have not been evaluated for their efficacy in hematopoietic stem/progenitor cell transduction. We evaluated the efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2196b2d600596b75a23e90c7c582dde9
https://doi.org/10.1089/hum.2006.17.321
https://doi.org/10.1089/hum.2006.17.321
Autor:
Mengqun Tan, Jonathan J. Hansen, Keyun Qing, Kirsten A. Weigel-Kelley, Shangzhen Zhou, Arun Srivastava
Publikováno v:
Journal of Virology. 75:8968-8976
Although adeno-associated virus type 2 (AAV) has gained attention as a potentially useful vector for human gene therapy, the transduction efficiencies of AAV vectors vary greatly in different cells and tissues in vitro and in vivo. We have documented
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3fd4615a98406b4157e8b2ba7734aee
https://doi.org/10.1128/jvi.75.19.8968-8976.2001
https://doi.org/10.1128/jvi.75.19.8968-8976.2001
Autor:
Mengqun Tan, Rebecca J. Chan, Li Zhong, Daniela Bischof, Arun Srivastava, Njeri Maina, Keyun Qing, Steven H. Larsen, Linyuan Chen, Yanjun Li, Weiming Li, Kirsten A. Weigel-Kelley, Weinian Shou, Mervin C. Yoder, Zuocheng Yang, Weihong Zhao, Jonathan J. Hansen
Publikováno v:
Human gene therapy. 15(12)
Controversies abound concerning hematopoietic stem cell transduction by recombinant adeno-associated virus 2 (AAV) vectors. For human hematopoietic cells, we have shown that this problem is related to the extent of expression of the cellular receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8896a02e999beaf67db03f1b7b8641c7
https://pubmed.ncbi.nlm.nih.gov/15684697
https://pubmed.ncbi.nlm.nih.gov/15684697
Autor:
Mervin C. Yoder, Li Zhong, Linyuan Chen, Keyun Qing, Yanjun Li, Arun Srivastava, Rebecca J. Chan, Kirsten A. Weigel-Kelley
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 10(5)
Recombinant vectors based on adeno-associated virus type 2 (AAV) target the liver efficiently, but the transgene expression is limited to approximately 5% of hepatocytes. The lack of efficient transduction is due, in part, to the presence of a cellul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a1e3e2d3356a50aa734fef73fc3fa4
https://pubmed.ncbi.nlm.nih.gov/15509512
https://pubmed.ncbi.nlm.nih.gov/15509512
Autor:
Mervin C. Yoder, Keyun Qing, Li Zhong, Arun Srivastava, Weinian Shou, Weiming Li, Linyuan Chen, Zhenyun Yang, Yan Li, Kirsten A. Weigel-Kelley
Publikováno v:
Gene therapy. 11(14)
Adeno-associated virus 2 (AAV) vectors are currently in use in Phase I/II clinical trials for gene therapy of cystic fibrosis and hemophilia B. Although 100% of murine hepatocytes can be targeted by AAV vectors, the transgene expression is limited to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb294047a019c94c7ea27bebbebbad6
https://pubmed.ncbi.nlm.nih.gov/15164097
https://pubmed.ncbi.nlm.nih.gov/15164097
Publikováno v:
Blood. 102(12)
Replication of the pathogenic human parvovirus B19 is restricted to erythroid progenitor cells. Although blood group P antigen has been reported to be the cell surface receptor for parvovirus B19, a number of nonerythroid cells, which express P antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7113f9d99c77503e8b3b866dcd7b0732
https://pubmed.ncbi.nlm.nih.gov/12907437
https://pubmed.ncbi.nlm.nih.gov/12907437
Publikováno v:
Pathologie-biologie. 50(5)
In an attempt to exploit the remarkable tissue-tropism of the human parvovirus B19 to target human hematopoietic cells of the erythroid lineage, recombinant human adeno-associated virus 2 genomes were encapsidated in parvovirus B19 capsids. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::066f419a3014de6311cabff8a2c5dddf
https://pubmed.ncbi.nlm.nih.gov/12116848
https://pubmed.ncbi.nlm.nih.gov/12116848
Publikováno v:
Journal of virology. 75(9)
The blood group P antigen, known to be abundantly expressed on erythroid cells, has been reported to be the cellular receptor for parvovirus B19. We have described the development of recombinant parvovirus B19 vectors with which high-efficiency, eryt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2d0afd19dd248ef49c1a7ecf4b1a85
https://pubmed.ncbi.nlm.nih.gov/11287560
https://pubmed.ncbi.nlm.nih.gov/11287560
Publikováno v:
Human Gene Therapy. :060913044654007
Most viral vectors used for gene therapy lack the ability to target a defined cell population. Parvovirus B19 has a restricted tropism for human erythroid progenitor cells and uses activated alpha5beta1 integrins as coreceptors for entry [Weigel-Kell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d070750ae0b278c440ba3d163ce1f748
https://doi.org/10.1089/hum.2006.17.ft-236
https://doi.org/10.1089/hum.2006.17.ft-236